Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 20/20 | 0.87 |
| ▸ | CTSG | P08311 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2697516 | 0.93 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL2698131 | 0.93 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL2697508 | 0.93 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL2696601 | 0.90 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL2698378 | 0.90 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL2696609 | 0.90 | CMA1 (1.00) | CMA1CTSG | |
| SCHEMBL4547808 | 0.90 | CMA1 (0.72) | CMA1CTSG | |
| SCHEMBL3644827 | 0.89 | CMA1 (0.79) | CMA1CTSG | |
| SCHEMBL3647510 | 0.89 | CMA1 (0.79) | CMA1CTSG | |
| SCHEMBL3647507 | 0.89 | CMA1 (0.79) | CMA1CTSG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-8501749-B2 | Azaquinazolinediones chymase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-08-06 | — | — | US | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108597-A1 | Azaquinazolinediones Chymase Inhibitors | CMA1, SERPINB1, CTSC | CMA1 1/4885CTSG 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.